Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Dec;60(6):855–860. doi: 10.1038/bjc.1989.379

Enhanced recognition of human colorectal tumour cells using combinations of monoclonal antibodies.

L G Durrant 1, R A Robins 1, K C Ballantyne 1, R A Marksman 1, J D Hardcastle 1, R W Baldwin 1
PMCID: PMC2247249  PMID: 2481485

Abstract

Murine monoclonal antibodies directed against tumour associated antigens are potentially useful in tumour diagnosis and therapy. However, all the antigens they recognise may be heterogeneously expressed on tumours and this may allow escape of cells from therapy if a single monoclonal antibody is used. One approach is to use combinations of monoclonal antibodies recognising complementary cell surface antigens. A flow cytometric method which allows accurate quantitation of the intensity of staining and the percentage of fresh primary tumour cells binding a series of monoclonal antibodies has therefore been developed. This allows calculations as the number of drug molecules which could be potentially delivered by each monoclonal antibody and the optimal combination of antibodies which should be used. Monoclonal antibodies recognising Y hapten (C14), CEA (228, 161) and 791T-p72 antigen (791T/36) have been screened as a possible combination for colorectal cancer. There was inter-tumour variation in the binding of all the monoclonal antibodies although combinations could reduce or abrogate this problem. A combination of the monoclonal antibodies C14, 228, 791T/36 and 161 would recognise 100% of tumours. Sixty per cent of tumours bound all four antibodies, 78% any three, 90% any two and 100% any one antibody. There was also intra-tumour variation in the number of tumour cells per lesion that were recognised, the best monoclonal antibody, 161, stained a mean of 59% of cells per tumour whereas the anti-cytokeratin monoclonal antibody stained a mean of 74% of cells per tumour. An increased intensity of staining of tumour membranes was observed when a combination of C14 and 228 was used compared to binding of individual antibodies. Furthermore there was still no significant binding to normal colon membranes. Combinations of monoclonal antibodies which recognise a high percentage of tumours are likely to be necessary for monoclonal antibody drug targeting to prevent tumour recurrence and/or metastases.

Full text

PDF
855

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe K., Hakomori S., Ohshiba S. Differential expression of difucosyl type 2 chain (LeY) defined by monoclonal antibody AH6 in different locations of colonic epithelia, various histological types of colonic polyps, and adenocarcinomas. Cancer Res. 1986 May;46(5):2639–2644. [PubMed] [Google Scholar]
  2. Besterman J. M., Low R. B. Endocytosis: a review of mechanisms and plasma membrane dynamics. Biochem J. 1983 Jan 15;210(1):1–13. doi: 10.1042/bj2100001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brattain M. G., Fine W. D., Khaled F. M., Thompson J., Brattain D. E. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 1981 May;41(5):1751–1756. [PubMed] [Google Scholar]
  4. Brown A., Ellis I. O., Embleton M. J., Baldwin R. W., Turner D. R., Hardcastle J. D. Immunohistochemical localization of Y hapten and the structurally related H type-2 blood-group antigen on large-bowel tumours and normal adult tissues. Int J Cancer. 1984 Jun 15;33(6):727–736. doi: 10.1002/ijc.2910330604. [DOI] [PubMed] [Google Scholar]
  5. Brown A., Feizi T., Gooi H. C., Embleton M. J., Picard J. K., Baldwin R. W. A monoclonal antibody against human colonic adenoma recognizes difucosylated Type-2-blood-group chains. Biosci Rep. 1983 Feb;3(2):163–170. doi: 10.1007/BF01121947. [DOI] [PubMed] [Google Scholar]
  6. Byers V. S., Pawluczyk I., Pawlucyzk I., Berry N., Durrant L., Robins R. A., Garnett M. C., Price M. R., Baldwin R. W. Potentiation of anti-carcinoembryonic antigen immunotoxin cytotoxicity by monoclonal antibodies reacting with co-expressed carcinoembryonic antigen epitopes. J Immunol. 1988 Jun 1;140(11):4050–4055. [PubMed] [Google Scholar]
  7. Ceriani R. L., Blank E. W., Peterson J. A. Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components. Cancer Res. 1987 Jan 15;47(2):532–540. [PubMed] [Google Scholar]
  8. Dalchau R., Kirkley J., Fabre J. W. Monoclonal antibody to a human leukocyte-specific membrane glycoprotein probably homologous to the leukocyte-common (L-C) antigen of the rat. Eur J Immunol. 1980 Oct;10(10):737–744. doi: 10.1002/eji.1830101003. [DOI] [PubMed] [Google Scholar]
  9. Dexter D. L., Spremulli E. N., Fligiel Z., Barbosa J. A., Vogel R., VanVoorhees A., Calabresi P. Heterogeneity of cancer cells from a single human colon carcinoma. Am J Med. 1981 Dec;71(6):949–956. doi: 10.1016/0002-9343(81)90312-0. [DOI] [PubMed] [Google Scholar]
  10. Durrant L. G., Robins R. A., Armitage N. C., Brown A., Baldwin R. W., Hardcastle J. D. Association of antigen expression and DNA ploidy in human colorectal tumors. Cancer Res. 1986 Jul;46(7):3543–3549. [PubMed] [Google Scholar]
  11. Embleton M. J., Gunn B., Byers V. S., Baldwin R. W. Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer. 1981 May;43(5):582–587. doi: 10.1038/bjc.1981.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ernst C. S., Shen J. W., Litwin S., Herlyn M., Koprowski H., Sears H. F. Multiparameter evaluation of the expression in situ of normal and tumor-associated antigens in human colorectal carcinoma. J Natl Cancer Inst. 1986 Aug;77(2):387–395. [PubMed] [Google Scholar]
  13. Farrands P. A., Perkins A. C., Pimm M. V., Embleton M. J., Hardy J. D., Baldwin R. W., Hardcastle J. D. Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet. 1982 Aug 21;2(8295):397–400. doi: 10.1016/s0140-6736(82)90437-8. [DOI] [PubMed] [Google Scholar]
  14. Garnett M. C., Baldwin R. W. An improved synthesis of a methotrexate-albumin-791T/36 monoclonal antibody conjugate cytotoxic to human osteogenic sarcoma cell lines. Cancer Res. 1986 May;46(5):2407–2412. [PubMed] [Google Scholar]
  15. Garnett M. C., Baldwin R. W. Endocytosis of a monoclonal antibody recognising a cell surface glycoprotein antigen visualised using fluorescent conjugates. Eur J Cell Biol. 1986 Aug;41(2):214–221. [PubMed] [Google Scholar]
  16. Herlyn M., Steplewski Z., Herlyn D., Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1438–1442. doi: 10.1073/pnas.76.3.1438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Krizan Z., Murray J. L., Hersh E. M., Rosenblum M. G., Glenn H. J., Gschwind C. R., Carlo D. J. Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants. Cancer Res. 1985 Oct;45(10):4904–4909. [PubMed] [Google Scholar]
  18. Lindholm L., Holmgren J., Svennerholm L., Fredman P., Nilsson O., Persson B., Myrvold H., Lagergård T. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol. 1983;71(2):178–181. doi: 10.1159/000233384. [DOI] [PubMed] [Google Scholar]
  19. Lloyd K. O., Larson G., Strömberg N., Thurin J., Karlsson K. A. Mouse monoclonal antibody F-3 recognizes the difucosyl type-2 blood group structure. Immunogenetics. 1983;17(5):537–541. doi: 10.1007/BF00696877. [DOI] [PubMed] [Google Scholar]
  20. Makin C. A., Bobrow L. G., Bodmer W. F. Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol. 1984 Sep;37(9):975–983. doi: 10.1136/jcp.37.9.975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McKenzie J. L., Fabre J. W. Human thy-1: unusual localization and possible functional significance in lymphoid tissues. J Immunol. 1981 Mar;126(3):843–850. [PubMed] [Google Scholar]
  22. Petricciani J. C., Smith P., Earley E. M., Levenbook I., Noguchi P. Characteristics of seven clones of the WiDr human colon adenocarcinoma cell line. In Vitro. 1982 May;18(5):492–494. doi: 10.1007/BF02796478. [DOI] [PubMed] [Google Scholar]
  23. Price M. R., Campbell D. G., Baldwin R. W. Identification of an anti-human osteogenic sarcoma monoclonal-antibody-defined antigen on mitogen-stimulated peripheral blood mononuclear cells. Scand J Immunol. 1983 Nov;18(5):411–420. doi: 10.1111/j.1365-3083.1983.tb00873.x. [DOI] [PubMed] [Google Scholar]
  24. Price M. R., Campbell D. G., Robins R. A., Baldwin R. W. Characteristics of a cell surface antigen defined by an anti-human osteogenic sarcoma monoclonal antibody. Eur J Cancer Clin Oncol. 1983 Jan;19(1):81–90. doi: 10.1016/0277-5379(83)90402-9. [DOI] [PubMed] [Google Scholar]
  25. Price M. R., Edwards S., Jacobs E., Pawluczyk I. Z., Byers V. S., Baldwin R. W. Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA. Cancer Immunol Immunother. 1987;25(1):10–15. doi: 10.1007/BF00199295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Spremulli E. N., Scott C., Campbell D. E., Libbey N. P., Shochat D., Gold D. V., Dexter D. L. Characterization of two metastatic subpopulations originating from a single human colon carcinoma. Cancer Res. 1983 Aug;43(8):3828–3835. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES